Welcome to our dedicated page for Deciphera Pharma news (Ticker: DCPH), a resource for investors and traders seeking the latest updates and insights on Deciphera Pharma stock.
Deciphera Pharmaceuticals (DCPH) is a biotechnology innovator advancing targeted therapies for cancer through its expertise in kinase inhibition. This page provides investors and industry professionals with verified updates on the company's clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements including quarterly earnings reports, FDA filings, clinical trial data, and partnership agreements. Our curated collection ensures you stay informed about DCPH's progress in developing small molecule therapeutics, particularly following its integration with Ono Pharmaceutical's global oncology network.
Key updates cover research breakthroughs, pipeline advancements, and operational developments within the company's Boston and Kansas research hubs. Bookmark this page for direct access to primary source materials and objective analysis of Deciphera's position in the competitive oncology therapeutics landscape.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) has announced that it will release its first quarter 2023 financial results on May 3, 2023, at 8:00 AM ET. A live conference call will follow to discuss the results and provide a corporate update. Interested parties can access the call through a designated link or via the company’s website. Deciphera focuses on developing innovative medicines for cancer patients, leveraging its proprietary switch-control kinase inhibitor platform. The company’s product, QINLOCK®, is a switch-control inhibitor approved for fourth-line treatment of GIST in several regions, including the U.S. and European Union. For more details, visit deciphera.com.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that its management will participate in a fireside chat at the Stifel Virtual Targeted Oncology Days on April 26, 2023, at 10:30 AM ET. The event aims to discuss the company's progress in developing innovative medicines for cancer treatment.
A live webcast will be accessible on the Company’s website under the “Investors” section, with an archived replay available for 90 days post-event. Deciphera's focus is on commercializing new treatments, notably QINLOCK®, a switch-control kinase inhibitor approved in multiple countries including the US, Canada, and the EU for the treatment of fourth-line GIST.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that QINLOCK is now included in the NCCN Guidelines as a preferred regimen for second-line gastrointestinal stromal tumor (GIST) patients intolerant to sunitinib. The FDA granted Breakthrough Therapy Designation for QINLOCK, indicating its potential to improve treatment outcomes for adult patients with unresectable or metastatic GIST with specific mutations. The company plans to initiate the INSIGHT Phase 3 Study in late 2023, aimed at evaluating QINLOCK against sunitinib in similar patient populations. This follows positive results from the INTRIGUE study, demonstrating QINLOCK's efficacy and tolerability profile.
FAQ
What is the current stock price of Deciphera Pharma (DCPH)?
What is the market cap of Deciphera Pharma (DCPH)?
